Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EP300 | Q09472 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 10/20 | 0.35 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.32 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.30 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
| ▸ | CES2 | O00748 | 1/20 | 0.30 |
| ▸ | CES1 | P23141 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | POLA1 | P09884 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7106223 | 1.00 | EP300 (0.42) | EP300FAAHGRIK1ZDHHC7ACHE | |
| SCHEMBL7101311 | 0.95 | EP300 (0.49) | EP300FAAH | |
| SCHEMBL7101314 | 0.95 | EP300 (0.49) | EP300FAAH | |
| SCHEMBL7104826 | 0.89 | EP300 (0.32) | EP300FAAH | |
| SCHEMBL7104828 | 0.89 | EP300 (0.32) | EP300FAAH | |
| SCHEMBL2152202 | 0.85 | EP300 (0.50) | EP300GRIK1ACHEEPHX1TSHR | |
| SCHEMBL7106635 | 0.85 | FAAH (0.44) | EP300FAAH | |
| SCHEMBL7106636 | 0.85 | FAAH (0.44) | EP300FAAH | |
| SCHEMBL7105155 | 0.83 | EP300 (0.40) | EP300FAAHGRIK1TSHR | |
| SCHEMBL7105156 | 0.83 | EP300 (0.40) | EP300FAAHGRIK1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1000939-B1 | Producing z-isomer of hydrogen bromide salt of 2-aminothiazole derivative | SUMITOMO CHEMICAL CO (JP) | 2003-09-17 | — | — | EP | disclosed |
| US-6403572-B1 | REACTING ACID SALT OF A 2-AMINOTHIAZOLE COMPOUND WITH INORGANIC ACID | SUMITOMO CHEMICAL CO., LTD. (JP) | 2002-06-11 | — | — | US | disclosed |
| US-20020058818-A1 | Producing Z-isomer of hydrogen bromide salt of 2-aminothiazole derivative | SUMITOMO CHEMICAL CO., LTD. | 2002-05-16 | — | — | US | disclosed |
| US-6340763-B1 | SALT FORMATION AND CRYSTALLIZATION, REACTION OF HALOGENATED COMPOUND AND THIOUREA COMPOUND | SUMITOMO CHEMICAL CO., LTD. (JP) | 2002-01-22 | — | — | US | disclosed |
| EP-1000939-A1 | Producing z-isomer of hydrogen bromide salt of 2-aminothiazole derivative | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2000-05-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020058818-A1 | Producing Z-isomer of hydrogen bromide salt of 2-aminothiazole derivative | ZYX, H1-0, HAO2 | EP300 2578/4885FAAH 4261/4885GRIK1 272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.